210 likes | 221 Views
Explore the cutting-edge field of nanomedicine, which applies nanotechnology to improve prevention, diagnosis, and treatment of diseases. This vision document presents the potential impact and advancements in nanomedicine.
E N D
La Nanomedicina Prof. Dr. Josep Samitier Univ. De Barcelona Lab Nanobioingeniería (IBEC) Coordinador Plataforma Española de Nanomedicina Director Adjunto CIBER BBN
Nuevas Tecnologías Miniaturización Técnicas clásicas (Macro) Microdispositivos Nanotecnología Convergencia de tecnologías Richard Feynman
Definition: NanoMedicine, for the purpose of this vision document, is defined as the application of Nanotechnology to Health. It exploits the improved and often novel physical, chemical, and biological properties of materials at the nanometric scale. NanoMedicine has potential impact on the prevention, early and reliable diagnosis and treatment of diseases.
NIH Nanomedicine Roadmap Initiative, emprendida por el Instituto Nacional de Salud de EE.UU en mayo de 2004 (http://www.capconcorp.com/roadmap04/) ESF Scientific Forward Look on Nanomedicine, presentado por el comité de expertos de la European Science Foundation en febrero de 2005 (http://www.esf.org/newsrelease/83/SPB23Nanomedicine.pdf) EuroNanoForum 2005, Nanotechnology and the Health of the EU Citizen in 2020 (Edimburgo, 6 – 9 septiembre de 2005). Entorn internacional
PRESENTACIÓN DEL INFORME PLATAFORMA ESPAÑOLA DE NANOMEDICINA
PLATAFORMA ESPAÑOLA DE NANOMEDICINA Jornadas de Plataformas Tecnológicas Josep Samitier Parc Científic de Barcelona-Univ. de Barcelona Institut de Bioenginyeria de Catalunya (IBEC)
MIEMBROS 108 grupos diferentes
GRUPOS DE TRABAJO • Nanodiagnóstico • Medicina Regenerativa • Liberación de Fármacos • Educación / Comunicación • Toxicidad / Regulación
MIEMBROS Por Comunidades Autónomas
EURONANOBIO WP1 Experts Workshop Nanobio Clusters: identifying best practices Dr Arantxa Sanz Prof. Josep Samitier Institute for Bioengineering of Catalonia (IBEC) Barcelona, SPAIN
WP1:OBJECTIVES AND METHOD GLOBAL OBJECTIVE: Identifying best practices across the most successful clusters As integration is key to success in nanobio, success = high quality, common research projects and results (with diverse cluster members as partners) DATA COLLECTION and ANALYSIS: METHODOLOGY (Feb-May 09) • Definition of a nanobio cluster in the study: research vs innovation cluster • Mapping clusters elsewhere: USA, Canada, Asia-Pacific • Mapping clusters in Europe • Identifying best practices via SWOT analysis • Consolidation workshop: discussion and brainstorming
Clinical Research Innovation Cluster agency Cluster agency non specific USA: mapping preliminary results BAY AREA SOUTH CALIFORNIA HOUSTON CHICAGO BOSTON CORNELL N. CAROLINA …
Clinical Research Innovation Cluster agency Cluster agency non specific ASIA PACIFIC – preliminary results TSUKUBA / TOKYO KOBE YONSEI (SEOUL) SINGAPORE SIDNEY …
Clinical Research Innovation Cluster agency Cluster agency non specific European Union: mapping preliminary results Most advanced nanobio clusters across EU + associate states: -Higher integration level of actors, including hospitals -Remarkable common output in terms of funded projects, research papers and patents / creation of spin off companies
SWOT analysis for the mapped clusters (some examples…) MÜNSTER – EXAMPLE